Progyny, Inc. (NASDAQ:PGNY) Stock Has Average Price Target of $34.36 According to Brokerages

Shares of Progyny, Inc. (NASDAQ:PGNY) have been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $34.36.

PGNY has been the subject of several research analyst reports. Truist Financial increased their price objective on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. boosted their target price on Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, August 21st. Citizens Jmp upped their target price on Progyny from $31.00 to $33.00 and gave the company a “market outperform” rating in a report on Tuesday, September 8th. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Finally, Jefferies Financial Group set a $33.00 price target on Progyny in a research note on Tuesday, September 8th.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $26.86 on Friday. The company has a 50-day moving average price of $26.40 and a 200-day moving average price of $25.52. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 29.20, a price-to-earnings-growth ratio of 1.85 and a beta of 1.02. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The company had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same period last year, the firm earned $0.19 earnings per share. Progyny’s quarterly revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, research analysts forecast that Progyny will post 1.25 EPS for the current fiscal year.

Insider Buying and Selling at Progyny

In other Progyny news, EVP Allison Swartz sold 3,903 shares of the company’s stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the completion of the transaction, the executive vice president directly owned 75,816 shares in the company, valued at approximately $1,978,797.60. This represents a 4.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa Cummings sold 1,879 shares of the company’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total transaction of $52,612.00. Following the completion of the transaction, the chief operating officer owned 66,496 shares of the company’s stock, valued at $1,861,888. This trade represents a 2.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 17,282 shares of company stock valued at $475,790. 9.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Progyny

A number of institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC purchased a new stake in Progyny in the second quarter worth $760,000. AWM Investment Company Inc. bought a new position in Progyny in the second quarter worth $6,343,000. Bank of America Corp DE raised its holdings in Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after purchasing an additional 511,609 shares in the last quarter. Squarepoint Ops LLC bought a new position in Progyny in the second quarter worth $1,705,000. Finally, Royal Bank of Canada raised its holdings in Progyny by 98.0% in the first quarter. Royal Bank of Canada now owns 218,434 shares of the company’s stock worth $3,709,000 after purchasing an additional 108,137 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Progyny Company Profile

Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.